PTC anticipates total revenues for full-year 2023 to be between $940 million and $1.0 billion. PTC anticipates net product revenue for the DMD franchise for full-year 2023 to be between $565 million and $595 million. PTC anticipates GAAP R&D and SG&A expenses for full-year 2023 to be between $915 million and $965 million. PTC anticipates Non-GAAP R&D and SG&A expenses for full year 2023 to be between $810 million and $860 million, excluding estimated non-cash stock-based compensation expense of $105 million. PTC expects to incur $37 million of one-time expenses related to the achievement of clinical success-based milestones from previous acquisitions and expenses associated with a rights exchange agreement, which have already been paid in equity and cash.